



**Business
Development
Opportunity**
*see overleaf
for details*

Addressing Bottlenecks in Drug Discovery

Evening Networking Event: Wednesday 21 October 2009,
Wellcome Collection, London

Benefits of attending:

- **EXPAND** your business network via our 1-2-1 partnering service
- **EXAMINE** the roles of pharma, biotech, academia and consortia in addressing the current bottlenecks of drug discovery
- **DISCOVER** cutting-edge innovations for predictive pharmacology and toxicology
- **LISTEN** to key industry personnel addressing the obstacles, and inviting solutions

Speakers include:

Dr Chas Bountra
The Structural Genomics Consortium

Dr Stewart Bates
GlaxoSmithKline

Dr Joern Werner
University of Southampton

Dr Lars Sundstrom
Capsant

Professor David Klug
Imperial College London

Supported by



For further information, contact **Lauren Gold** at
l.gold@LTNetwork.org or on **0870 730 8661**

© LTN 2009 programme may be subject to change

Addressing Bottlenecks in Drug Discovery

Despite the advent of high-throughput screening, combinatorial chemistry and informatics, the number of novel drugs reaching the market has consistently decreased over the past decade. With the cost of developing new drugs reaching \$1 billion and taking 10 years in the making, pharma companies, research institutions and investors alike are painfully aware of the inherent bottlenecks associated with drug discovery and development.

As industry strives to deliver safe and efficacious drugs to the market, their success is increasingly dependant upon the early stage identification of a drug's true potential (including its limitations) at the drug discovery stage. The aim of this event is to analyse what technologies and strategies are currently being employed in order to both refine and expedite this process, and overcome the various bottlenecks that face the pharmaceutical industry today.

- 17.45 Registration with tea and coffee
- 18.15 Introduction to the aims and objectives of London Technology Network
Maki Aoyama, Business Development Manager, **LTN**
- 18.25 **Accelerating the Hit-to-Lead Process**
- Addressing the major challenges facing the drug discovery process
 - Identifying and validating targets for drug discovery
 - Assessing the emerging opportunities and associated challenges facing pharmacological development
- Dr Chas Bountra**, Head of Structural Genomics Consortium, Chief Scientist, Unit Director, Member of congregation and Group Head, **The Structural Genomics Consortium**
- 18.40 **Novel Analytic Tools Providing New Ways to Negate Drug Discovery Bottlenecks**
- Addressing utility of ultra sensitive high-throughput optical analogues of 2DNMR
 - Discussing utility of single-cell proteomics
 - Platforms for screening protein-protein interactions
- Professor David Klug**, Chair of the Chemical Biology Centre, **Imperial College London**
- 18.55 **Predictive Toxicology: Utilising Stem Cell Research to Address Drug Toxicity**
- Analysing the potential of differentiating human stem cells into human tissues for early identification of drug toxicity
- Assessing the challenges of scaling up stem cell based systems
 - Evaluating the next steps in *ex vivo* analysis
- Dr Lars Sundstrom**, Chief Scientific Officer, **Capsant**
- 19.10 **Translational Medicine to Expedite the Drug Discovery Process**
- The use of pre-clinical translational models to identify PD markers
 - Examining translational markers in human clinical samples
 - Discussing the use of human *ex vivo* models
- Dr Stewart Bates**, Director, Biomarker Discovery, **GlaxoSmithKline**
- 19.25 **Modelling Cellular Processes: A case study**
- Addressing the challenges in the identification of targets and mechanisms
 - Assessing cellular processes as reactive systems
 - Examining immunodominance and MHC-class 1 peptide loading
- Dr Joern Werner**, Reader in Biological Sciences, **University of Southampton**
- 19.45 Question and answer session from the audience with the speaker panel
- 20.00 Networking wine and buffet reception with poster showcase; 1-2-1 partnering sessions will be available.

BUSINESS DEVELOPMENT OPPORTUNITY

This unique event will be an excellent opportunity to initiate new relationships through tailored networking and a showcase of the latest academic research. LTN offers a range of sponsorship packages to enhance your brand, for further information contact **Nicole Honeyghan-Howe** on **0870 730 8687** or **n.honeyghan@ltnetwork.org**



**Emerging
Medical
Technologies**

A special interest group bringing together the best biomedical experts from industry, academia and government, across the Greater South-East, to stimulate knowledge exchange

The Group produces regular networking events on emerging bio-medical technologies which have discussed a range of topics, attracting over 800 representatives from across the public and private sectors. Membership is free and includes:

- Priority invitations to the group's seminars, workshops and networking events
- Regular e-newsletters, with the latest sector news and listings of UK and international events
- Access to Enterprise Europe Network – a multi-partner consortium spanning 40 countries across Europe

If you would like further information or would like to become a member of this group please contact Natalie Tamiollo, Special Interest Group Manager at n.tamiollo@LTNetwork.org or on 0870 730 8683

For further information, contact **Lauren Gold** at l.gold@LTNetwork.org
or on **0870 730 8661**

Registration & Payment

Payment: Commercial - £80.00 (+VAT = £12.00) - £92.00

Small / medium companies (50-149 employees) £60.00 (+VAT = £9.00) - £69.00

Micro companies (49 employees and below) £40.00 (+VAT = £6.00) - £46.00

Academic (based in the Greater South East)* - Free

*Academic rate is extended to full-time employees of government, universities and university-affiliated hospitals only

All payments must be received prior to the conference and should be made within 14 days of receiving a provisional place. Attendance will be confirmed upon receipt of payment. Prices include all refreshments and delegate documentation. All LTN events are by invitation to ensure that the quality of interaction is maintained. The purpose of our events is to encourage collaboration between industry and academia. You are welcome to invite people whom you think would be interested, however LTN reserves the right to decline applications. To apply for an invitation, and to find out about different payment methods, please email **Lauren Gold** at l.gold@LTNetwork.org. **Cancellations must be made at least 7 days prior to the event.**

HOW TO GET THERE

This event will take place at **The Wellcome Collection, 183 Euston Rd, London, NW1 2BE**

Tel: **020 7611 2222**. For a more detailed view, please go to:

<http://www.wellcomecollection.org/visitus/index.htm>



The Wellcome Collection is easily accessible by public transport

By train The nearest mainline stations are Euston, St Pancras and King's Cross.

By tube Euston station: Victoria and Northern lines

Euston Square station: Circle, Metropolitan, and Hammersmith and City lines

Warren Street station: Victoria and Northern lines

King's Cross station: Victoria, Northern, Circle, Metropolitan, and Hammersmith and City lines

By bus The following buses pass near Wellcome Collection:

10 : 18 : 24 : 27 : 29 : 30 : 59 : 68 : 73 : 88 : 91 : 134 : 168 : 205 : 253 : 390

For further information, contact **Lauren Gold** at l.gold@LTNetwork.org
or on **0870 730 8661**

© LTN 2009 programme may be subject to change